Conclusively, our mice xenograft studies showed that olaparib-mediated reduction of prostate tumor growth and metastases is potentiated by inhibition of MALAT1. These findings suggest that targeting MALAT1 enhances the vulnerability of prostate cancer to PARPi therapy. The gene discussed is MALAT1; the disease is prostate neoplasm.